| Adenosines/P2 Nucleotide Receptors (Purinergics) |
|
|
| Product Name |
Product # |
Specificity |
| Adenosine agonists |
|
|
| Adenosine amine congener solid |
A-111 |
A1 |
| 2-Chloro-N6-cyclopentyladenosine solid |
C-142 |
A1 |
| N6-Cyclohexyladenosine |
C9901 |
A1 |
| N6-Cyclopentyladenosine solid |
C8031 |
A1 |
| (S)-ENBA |
E-111 |
A1 |
| (-)-N6-(2-Phenylisopropyl)adenosine solid |
P4532 |
A1 |
| N6-p-Sulfophenyladenosine sodium salt solid |
S-198 |
A1 |
| (+)-N6-(2-Phenylisopropyl)adenosine |
P7665 |
A1; less active enantiomer |
| 2-Chloroadenosine |
C5134 |
A1,A2 |
| N6-Phenyladenosine solid |
P-108 |
A1,A2 |
| N6-(2-Phenylethyl)adenosine |
P-107 |
A1,A2 |
| Metrifudil |
M-225 |
A2 |
| MECA solid |
A-024 |
A2,A1 |
| 2-Phenylaminoadenosine >97 % solid |
P-101 |
A2,A1 |
| HE-NECA solid |
H8034 |
A2,A3 |
| CGS-21680 hydrochloride solid |
C-141 |
A2A |
| DPMA solid |
D-130 |
A2A |
| 5'-(N-Ethylcarboxamido)adenosine powder |
E2387 |
A2B |
| N6-(4-Aminobenzyl)-N-methylcarboxamidoadenosine solid |
A-236 |
A3 |
| N6-2-(4-Aminophenyl)ethyladenosine >95 % |
A-202 |
A3 |
| N6-Benzyl-5'-N-ethylcarboxamidoadenosine solid |
B-152 |
A3 |
| Chloro-IB-MECA solid |
C-277 |
A3 |
| IB-MECA solid |
I-146 |
A3 |
| I-AB-MECA solid |
I-145 |
A3 probe |
| Adenosine min. 99 % |
A9251 |
Endogenous |
| Adenosine hemisulfate salt min. 98 % |
A7636 |
Endogenous |
| Adenosine antagonists |
back to top |
| CGS-15943 solid |
C-199 |
A1 |
| 7-Chloro-4-hydroxy-2-phenyl-1,8-naphthyridine solid |
C5982 |
A1 |
| 8-Cyclopentyl-1,3-dimethylxanthine crystalline |
C-102 |
A1 |
| 8-Cyclopentyl-1,3-dipropylxanthine solid |
C-101 |
A1 |
| 1,3-Dimethyl-8-phenylxanthine crystalline |
P2278 |
A1 |
| FSCPX |
F7927 |
A1 |
| Xanthine amine congener |
X-103 |
A1 |
| 1,7-Dimethylxanthine approx. 98 % solid |
D5385 |
A1 > A2 |
| 1,3-Dipropyl-8-(p-sulfophenyl)xanthine solid |
A-022 |
A1 > A2 |
| 3-Isobutyl-1-methylxanthine min. 99 % (HPLC) powder |
I5879 |
A1 > A2 |
| 3-Propylxanthine min. 99 % solid |
P5679 |
A1 > A2 |
| 8-(p-Sulfophenyl)theophylline solid |
A-013 |
A1 > A2 |
| Theophylline anhydrous min. 99 % powder |
T1633 |
A1 > A2 |
| 3,7-Dimethyl-1-propargylxanthine solid |
D-134 |
A2 |
| Aminophylline hydrate min. 98 % powder |
A1755 |
A2 > A1 |
| 8-(3-Chlorostyryl)caffeine solid |
C-197 |
A2A |
| SCH-58261 99 % (HPLC) solid |
S4568 |
A2A |
| Alloxazine solid |
A-242 |
A2B |
| MRS 1754 >98 % (HPLC) |
M6316 |
A2B |
| MRS 1191 solid |
M-227 |
A3 |
| MRS 1220 solid |
M-228 |
A3 |
| MRS 1523 >98 % (HPLC) |
M1809 |
A3 |
| VUF 5574 |
V5888 |
A3 |
| Enzyme inhibitors |
back to top |
| erythro-9-(2-Hydroxy-3-nonyl)adenine hydrochloride solid |
E-114 |
Adenosine deaminase |
| P2 Receptor agonists |
back to top |
| Cytidine 5'-triphosphate disodium salt approx. 98 % |
C1506 |
Endogenous |
| Adenosine 5'-[g-thio]triphosphate tetralithium salt min. 75 % powder |
A1388 |
P2 |
| Adenosine 5'-triphosphate disodium salt Grade I min. 99 % |
A2383 |
P2 |
| 2-(Methylthio)adenosine 5'-diphosphate trisodium salt >89 % solid |
M-152 |
P2 |
| 2-(Methylthio)adenosine 5'-triphosphate tetrasodium salt >91 % solid |
A-023 |
P2 |
| Adenosine 5'-[b-thio]diphosphate trilithium salt min. 80 % |
A8016 |
P2X |
| 8-Bromoadenosine 5'-triphosphate sodium salt approx. 95 % |
B3756 |
P2X |
| P1,P4-Di(adenosine-5') tetraphosphate ammonium salt approx. 95 % (HPLC) powder |
D1262 |
P2X |
| a,b-Methyleneadenosine 5'-triphosphate lithium salt min. 95 % solid |
M6517 |
P2X > P2Y |
| b,g-Methyleneadenosine 5'-triphosphate disodium salt min. 95 % solid |
M7510 |
P2X > P2Y |
| Adenosine 5'-diphosphate monopotassium salt dihydrate bacterial 98-100 % crystalline |
A5285 |
P2X1 |
| Cytidine 5'-triphosphate disodium solution |
C8552 |
P2X3 |
| 2-Chloroadenosine triphosphate tetrasodium salt solid |
C-145 |
P2Y |
| Uridine 5'-triphosphate trisodium salt solution |
U1006 |
P2Y2 |
| Uridine 5'-diphosphate sodium salt from Saccharomyces cerevisiae 95-100 % |
U4125 |
P2Y6 |
| P2 Receptor antagonists |
back to top |
| P2 Receptor antagonists solid |
P-178 |
P2 |
| Suramin sodium salt min. 95 % solid |
S2671 |
P2 |
| NF 023 crystalline |
N8652 |
P2X1/3 |
| TNP-ATP solid |
T4193 |
P2X1/3 |
| Diinosine pentaphosphate pentasodium salt |
D6938 |
P2X1 |
| MRS 2159 >98 % (HPLC) solid |
M7684 |
P2X1 |
| PPNDS solid |
P2738 |
P2X1 |
| Brilliant Blue G min. 90 % (TLC) |
B5133 |
P2X7 |
| Adenosine 2',5'-diphosphate sodium salt min. 95 % |
A5638 |
P2Y |
| Adenosine 3',5'-diphosphate sodium salt approx. 97 % |
A5763 |
P2Y |
| Reactive Blue 2 solid |
R-115 |
P2Y |
| MRS 2179 >98 % (HPLC) |
M3808 |
P2Y1 |
| MRS 2395 ³98 % (HPLC) solid |
M5942 |
P2Y12 |
| Transporter |
|
|
| Adenosine Transporter Receptor human Membrane suspension |
A8352 |
|
| Transport inhibitors |
back to top |
| Dilazep dihydrochloride powder |
D5294 |
|
| Dipyridamole min. 98 % (TLC) powder |
D9766 |
|
| 5-Iodotubericidin solid |
I-100 |
|
| S-(4-Nitrobenzyl)-6-thioinosine min. 98 % solid |
N2255 |
|
| Adrenergics |
|
back to top |
| Product Name |
Product # |
Specificity |
| Agonists |
|
|
| 6-Fluoronorepinephrine hydrochloride solid |
B-012 |
a |
| Mephentermine hemisulfate salt |
M3656 |
a |
| Metaraminol (+)-bitartrate salt |
M4773 |
a |
| (±)-Octopamine hydrochloride solid |
O0250 |
a |
| (±)-Synephrine min. 99 % |
S0752 |
a |
| Tetrahydrozoline hydrochloride min. 98 % |
T4264 |
a |
| Xylometazoline hydrochloride |
X6000 |
a |
| Dihydroergotamine methanesulfonate salt powder |
D2763 |
a (Partial) |
| (R)-(-)-Phenylephrine hydrochloride |
P6126 |
a1 |
| Cirazoline hydrochloride solid |
C-223 |
a1A |
| Methoxamine hydrochloride |
M6524 |
a1A, Aa1D |
| Naphazoline hydrochloride |
N5504 |
a1A, Aa1D |
| Agmatine sulfate salt min. 97 % powder |
A7127 |
a2 |
| p-Aminoclonidine hydrochloride solid |
A0779 |
a2 |
| B-HT 920 dihydrochloride solid |
B-162 |
a2 |
| B-HT 933 dihydrochloride solid |
B-161 |
a2 |
| Clonidine hydrochloride solid |
C7897 |
a2 |
| Guanabenz acetate salt solid |
G-110 |
a2 |
| Guanfacine hydrochloride >98 % (HPLC) |
G1043 |
a2 |
| Rilmenidine hemifumarate salt solid |
R-134 |
a2 |
| UK 14,304 |
U-104 |
a2 |
| Xylazine min. 99 % |
X1126 |
a2 |
| Xylazine hydrochloride min. 99 % |
X1251 |
a2 |
| Moxonidine hydrochloride min. 98 % |
M1559 |
a2A |
| Oxymetazoline hydrochloride solid |
O2378 |
a2A (partial) |
| Bambuterol hydrochloride >98 % (HPLC) powder |
B8684 |
b |
| (±)-CGP-12177 hydrochloride >98 % solid |
C-125 |
b |
| Isoetharine mesylate salt |
I3639 |
b |
| (±)-Isoproterenol hydrochloride |
I5627 |
b |
| (-)-Isoproterenol (+)-bitartrate salt |
I2760 |
b |
| (-)-Isoproterenol hydrochloride |
I6504 |
b |
| (±)-Isoproterenol hemisulfate salt |
I5752 |
b |
| Tulobuterol hydrochloride |
T6050 |
b |
| R(-)-Denopamine >98 % (HPLC) |
D7815 |
b1 |
| Dobutamine hydrochloride min. 98 % |
D0676 |
b1 |
| Xamoterol hemifumarate salt >98 % (HPLC) |
X3253 |
b1 (Partial) |
| Clenbuterol hydrochloride min. 95 % |
C5423 |
b2 |
| Fenoterol hydrobromide |
F1016 |
b2 |
| Formoterol fumarate >98 % (HPLC) |
F9552 |
b2 |
| Metaproterenol hemisulfate salt |
M2398 |
b2 |
| Procaterol hydrochloride |
P9180 |
b2 |
| Ritodrine hydrochloride |
R0758 |
b2 |
| Salbutamol |
S8260 |
b2 |
| Salbutamol hemisulfate salt |
S5013 |
b2 |
| Salmeterol >98 % (HPLC) solid |
S2692 |
b2 |
| Terbutaline hemisulfate salt |
T2528 |
b2 |
| BRL 37344 sodium salt powder |
B-169 |
b3 |
| CL 316,243 min. 98 % |
C5976 |
b3 |
| (-)-Epinephrine |
E4250 |
Endogenous a, b |
| (-)-Epinephrine (+)-bitartrate salt solid |
E4375 |
Endogenous a, b |
| (±)-Epinephrine min. 98 % |
E1635 |
Endogenous a, b |
| (±)-Epinephrine hydrochloride |
E4642 |
Endogenous a, b |
| (-)-Norepinephrine (+)-bitartrate salt hydrate min. 99 % solid |
A9512 |
Endogenous a, b1 |
| (-)-Norepinephrine min. 98 % crystalline |
A7257 |
Endogenous a, b1 |
| (±)-Norepinephrine (+)-bitartrate salt |
A0937 |
a, b1 |
| (+)-Isoproterenol (+)-bitartrate salt |
I8005 |
Less active enantiomer |
| Antagonists |
|
|
| Phenoxybenzamine hydrochloride min. 97 % powder |
B-019 |
a |
| Phentolamine hydrochloride min. 99 % (TLC) powder |
P7547 |
a |
| Phentolamine methanesulfonate salt min. 99 % (TLC) powder |
P7561 |
a |
| Spiroxatrine powder |
S-103 |
a |
| Terazosin hydrochloride min. 98 % (TLC) powder |
T4680 |
a |
| R(+)-Atenolol solid |
A-142 |
a1 |
| Benoxathian hydrochloride solid |
B-016 |
a1 |
| Doxazosin mesylate >98 % (HPLC) |
D9815 |
a1 |
| Fiduxosin hydrochloride >98 % (HPLC) |
F4303 |
a1 |
| Moxisylyte hydrochloride >99 % (TLC) powder |
M5154 |
a1 |
| Naftopidil dihydrochloride solid |
N-158 |
a1 |
| Urapidil hydrochloride solid |
U-100 |
a1 |
| Prazosin hydrochloride min. 99 % (TLC) solid |
P7791 |
a1 (peripheral) |
| Prazobind solid |
P-124 |
a1 alkylating agent |
| 5-Methylurapidil solid |
U-101 |
a1A |
| (±)-Niguldipine hydrochloride solid |
N-134 |
a1A |
| S(+)-Niguldipine hydrochloride solid |
N-135 |
a1A |
| WB-4101 hydrochloride >99 % (TLC) solid |
D0411 |
a1A |
| L-765,314 min. 98 % |
L3040 |
a1B |
| Spiperone solid |
S7395 |
a1B |
| Chloroethylclonidine dihydrochloride solid |
B-003 |
a1B alkylating agent |
| A-315456 >98 % (HPLC) solid |
A6351 |
a1D |
| BMY 7378 dihydrochloride >98 % solid |
B-134 |
a1D |
| Efaroxan hydrochloride |
E3263 |
a2 |
| Idazoxan hydrochloride |
I6138 |
a2 |
| MK-912 hydrochloride salt >98 % (HPLC) |
M7065 |
a2 |
| Rauwolscine hydrochloride solid |
R-104 |
a2 |
| RX 821002 solid |
R9525 |
a2 |
| SKF 86466 solid |
S1563 |
a2 |
| Tolazoline hydrochloride min. 99 % (titration) powder |
T6886 |
a2 |
| Yohimbine hydrochloride min. 98 % (TLC) powder |
Y3125 |
a2 |
| BRL 44408 maleate >99 % (HPLC) solid |
B4559 |
a2A |
| Imiloxan hydrochloride >98 % (HPLC) |
I9531 |
a2B |
| Labetalol hydrochloride >99 % (TLC) powder |
L1011 |
b |
| (S)-(-)-Propranolol hydrochloride min. 99 % (TLC) powder |
P8688 |
b |
| (±)-Propranolol hydrochloride min. 99 % (TLC) powder |
P0884 |
b |
| (±)-Sotalol hydrochloride min. 98 % (TLC) powder |
S0278 |
b |
| Atenolol min. 98 % (TLC) powder |
A7655 |
b1 |
| S(-)-Atenolol solid |
A-143 |
b1 |
| Betaxolol hydrochloride >98 % (HPLC) |
B5683 |
b1 |
| CGP-20712A methanesulfonate salt solid |
C-231 |
b1 |
| Cyclazosin hydrochloride solid |
C-247 |
b1B |
| (±)-Metoprolol (+)-tartrate salt min. 99 % (titration) powder |
M5391 |
b1 |
| Timolol maleate salt min. 98 % (TLC) powder |
T6394 |
b1 |
| Alprenolol hydrochloride >99 % (TLC) powder |
A8676 |
b1, b2 |
| Pindolol min. 98 % (TLC) powder |
P0778 |
b1, b2 |
| S(–)-Pindolol solid |
P-152 |
b1, b2 |
| ICI 118,551 hydrochloride min. 99 % (TLC) powder |
I-127 |
b2 |
| Bromoacetyl alprenolol menthane powder |
B-015 |
b2 > b1 alkylating agent |
| S(-)-Cyanopindolol hemifumarate salt solid |
C-238 |
b3 |
| SR 59230A oxalate salt solid |
S8688 |
b3 |
| (R)-(+)-Propranolol hydrochloride min. 99 % (TLC) powder |
P0689 |
Less active enantiomer |
| Enzyme inhibitors |
|
|
| Benserazide hydrochloride min. 98 % (TLC) solid |
B7283 |
L-Amino acid decarboxylase |
| S-(-)-Carbidopa >98 % solid |
C-126 |
L-Amino acid decarboxylase |
| S(-)-Carbidopa: HBC complex |
C-164 |
L-Amino acid decarboxylase |
| (±)-3-(3,4-Dihydroxyphenyl)-2-methyl-DL-alanine |
M7277 |
L-Amino acid decarboxylase |
| 3-Hydroxybenzylhydrazine dihydrochloride 95-98 % (TLC) |
H9382 |
L-Amino acid decarboxylase |
| Ro 41-0960 solid |
R-108 |
Catechol-O-methyltransferase |
| Fusaric acid from Gibberella fujikuroi |
F6513 |
Dopamine b-hydroxylase |
| 3-Phenylpropargylamine hydrochloride solid |
P-106 |
Dopamine b-hydroxylase |
| 1-Phenyl-3-(2-thiazolyl)-2-thiourea |
P4015 |
Dopamine b-hydroxylase |
| R-(-)-Deprenyl hydrochloride solid |
M-003 |
Monoamine oxidase |
| Hydralazine hydrochloride |
H1753 |
Monoamine oxidase |
| Hydroxylamine hydrochloride min. 99 % (titration) |
H9876 |
Monoamine oxidase |
| Hydroxylamine sulfate salt min. 99 % (titration) |
H0127 |
Monoamine oxidase |
| Iproniazid phosphate salt |
I7627 |
Monoamine oxidase |
| N-Methyl-N-propargyl-3-(2,4-dichlorophenoxy)propylamine hydrochloride |
M3778 |
Monoamine oxidase |
| Nialamide min. 95 % (HPLC) |
N1392 |
Monoamine oxidase |
| Pargyline hydrochloride |
P8013 |
Monoamine oxidase |
| Phenelzine sulfate salt |
P6777 |
Monoamine oxidase |
| trans-2-Phenylcyclopropylamine hemisulfate salt |
P1761 |
Monoamine oxidase |
| trans-2-Phenylcyclopropylamine hydrochloride |
P8511 |
Monoamine oxidase |
| Quinacrine dihydrochloride min. 90 % |
Q3251 |
Monoamine oxidase |
| Ro 41-1049 hydrochloride solid |
R-107 |
Monoamine oxidase |
| Ro 16-6491 hydrochloride solid |
R-106 |
Monoamine oxidase |
| (±)-2,3-Dichloro-a-methylbenzylamine hydrochloride solid |
D-103 |
Phenylethanolamine N-methyltransferase |
| 3-Iodo-L-tyrosine |
I8250 |
Tyrosine hydroxylase |
| a-Methyl-L-tyrosine |
M8131 |
Tyrosine hydroxylase |
| a-Methyl-DL-tyrosine methyl ester hydrochloride min. 98 % (TLC) |
M3281 |
Tyrosine hydroxylase |
| Enzymes |
|
|
| Catechol-O-methyl Transferase porcine liver Lyophilized powder min. 1,000 units/mg protein |
C1897 |
|
| Phenylethanolamine N-Methyltransferase from bovine adrenal medulla Lyophilized powder |
P8924 |
|
| Metabolites |
|
|
| DL-4-Hydroxy-3-methoxymandelic acid |
H0131 |
|
| 4-Hydroxy-3-methoxyphenylglycol hemipiperazinium salt |
H1377 |
|
| DL-Metanephrine hydrochloride min. 98 % (TLC) powder |
M8625 |
|
| 4-Hydroxy-3-methoxyphenylglycol sulfate potassium salt min. 98 % (HPLC) powder |
H8759 |
|
| DL-Normetanephrine hydrochloride min. 98 % |
N7127 |
|
| Neurotoxins |
|
|
| N-(2-Chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride min. 98 % |
C8417 |
|
| 6-Hydroxydopamine hydrobromide |
H-116 |
|
| 6-Hydroxydopamine hydrobromide min. 90 % (HPLC) solid |
H8523 |
|
| 6-Hydroxydopamine hydrochloride >97 % (titration) crystalline |
H4381 |
|
| 6-Hydroxy-DL-DOPA min. 98 % (TLC) powder |
H2380 |
|
| Others |
|
|
| AH 11110 >98 % (HPLC) solid |
A3477 |
a1A ligand |
| Precursors |
|
|
| DL-threo-b-(3,4-Dihydroxyphenyl)serine min. 99 % (HPLC) powder |
D2384 |
|
| Dopamine hydrochloride solid |
H8502 |
|
| L-Tyrosine min. 98 % (TLC) |
T3754 |
|
| L-Tyrosine disodium salt min. 98 % (TLC) powder |
T2269 |
|
| L-Tyrosine hydrochloride min. 98 % (TLC) |
T2006 |
|
| Receptors |
|
|
| b1-Adrenergic Receptor Human recombinant, expressed in Sf 9 cells Membrane suspension |
B-143 |
|
| b1-Adrenergic Receptor Preparation human Lyophilized powder |
A6728 |
|
| b2-Adrenergic Receptor human Membrane suspension recombinant, expressed in Sf 9 cells |
B-144 |
|
| a2A-Adrenergic Receptor human Membrane suspension recombinant, expressed in Sf 9 cells |
A-213 |
|
| a2A-Adrenergic Receptor Preparation human Membrane suspension |
A6853 |
|
| a2C-Adrenergic Receptor human Membrane suspension recombinant, expressed in Sf 9 cells |
A-214 |
|
| Release inhibitors |
|
|
| Bretylium tosylate >99 % (TLC) powder |
B8406 |
|
| Sympathomimetics |
|
|
| D-Amphetamine sulfate salt |
A5880 |
|
| DL-Amphetamine sulfate salt |
A1263 |
|
| Benzphetamine hydrochloride |
B8263 |
|
| Cathine hydrochloride from khat shrub (Arabia, Ethiopia) solid |
C-222 |
|
| S(-)-Cathinone hydrochloride |
C3196 |
|
| (+)-Methamphetamine hydrochloride |
M8750 |
|
| (±)-p-Methoxyamphetamine hydrochloride |
M3404 |
|
| 2-(Methylamino)propiophenone hydrochloride |
M5037 |
|
| (±)-N-Methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine hydrochloride solid |
M-200 |
|
| DL-Norephedrine hydrochloride min. 99 % |
P7876 |
|
| Phentermine hydrochloride |
P8653 |
|
| (+)-Pseudoephedrine hydrochloride |
E2750 |
|
| Transport inhibitors |
|
|
| Reserpine |
R0875 |
Vesicular transport inhibitors |
| Amoxapine |
A-129 |
|
| Cocaine hydrochloride |
C5776 |
|
| Cocaine free base |
C8912 |
|
| Desipramine hydrochloride min. 98 % (TLC) powder |
D3900 |
|
| Maprotiline hydrochloride >99 % (HPLC) powder |
M9651 |
|
| Nisoxetine hydrochloride solid |
N-151 |
|
| Nortriptyline hydrochloride min. 98 % (TLC) powder |
N7261 |
|
| Protriptyline hydrochloride min. 99 % (TLC) powder |
P8813 |
|
| Biogenic Amines |
|
back to top |
| Product Name |
Product # |
Specificity |
| Enzyme Inhibitors |
|
|
| Benserazide hydrochloride min. 98 % (TLC) solid |
B7283 |
L-Amino acid decarboxylase |
| S(-)-Carbidopa: HBC complex |
C-164 |
L-Amino acid decarboxylase |
| (±)-3-(3,4-Dihydroxyphenyl)-2-methyl-DL-alanine |
M7277 |
L-Amino acid decarboxylase |
| 3-Hydroxybenzylhydrazine dihydrochloride 95-98 % (TLC) |
H9382 |
L-Amino acid decarboxylase |
| R-(-)-Deprenyl hydrochloride solid |
M-003 |
Monoamine oxidase |
| Hydralazine hydrochloride |
H1753 |
Monoamine oxidase |
| Hydroxylamine hydrochloride min. 99 % (titration) |
H9876 |
Monoamine oxidase |
| Hydroxylamine sulfate salt min. 99 % (titration) |
H0127 |
Monoamine oxidase |
| Iproniazid phosphate salt |
I7627 |
Monoamine oxidase |
| N-Methyl-N-propargyl-3-(2,4-dichlorophenoxy)propylamine hydrochloride |
M3778 |
Monoamine oxidase |
| Nialamide min. 95 % (HPLC) |
N1392 |
Monoamine oxidase |
| Pargyline hydrochloride |
P8013 |
Monoamine oxidase |
| Phenelzine sulfate salt |
P6777 |
Monoamine oxidase |
| trans-2-Phenylcyclopropylamine hemisulfate salt |
P1761 |
Monoamine oxidase |
| trans-2-Phenylcyclopropylamine hydrochloride |
P8511 |
Monoamine oxidase |
| Quinacrine dihydrochloride min. 90 % |
Q3251 |
Monoamine oxidase |
| Ro 41-1049 hydrochloride solid |
R-107 |
Monoamine oxidase |
| Ro 16-6491 hydrochloride solid |
R-106 |
Monoamine oxidase |
| Nonselective releasers |
|
|
| D-Amphetamine sulfate salt |
A5880 |
|
| DL-Amphetamine sulfate salt |
A1263 |
|
| S(-)-Cathinone hydrochloride |
C3196 |
|
| (+)-Methamphetamine hydrochloride |
M8750 |
|
| (±)-3,4-Methylenedioxymethamphetamine hydrochloride |
M6403 |
|
| S(+)-3,4-Methylenedioxymethamphetamine hydrochloride solid |
M-139 |
|
| Transport enhancers |
|
|
| Tianeptine Sodium-Potassium salt solid |
T1692 |
Serotonin transport |
| Transport Inhibitors |
|
|
| Transport inhibitors >97 % solid |
F-133 |
Metabolite |
| Amitriptyline hydrochloride min. 98 % (TLC) powder |
A8404 |
Nonselective |
| Doxepin hydrochloride approx. 85 % as E-isomer min. 98 % (GC) 15 % as Z-isomer powder |
D4526 |
Nonselective |
| Fluoxetine hydrochloride solid |
F-132 |
Nonselective |
| R-(-)-Fluoxetine hydrochloride >98 % (HPLC) |
F1678 |
Nonselective |
| S-(+)-Fluoxetine hydrochloride >98 % (HPLC) |
F1553 |
Nonselective |
| Imipramine hydrochloride min. 98 % (TLC) crystalline |
I7379 |
Nonselective |
| Indatraline hydrochloride solid |
I-119 |
Nonselective |
| Mazindol min. 99 % (TLC) powder |
M2017 |
Nonselective |
| Mirtazapine ³99 % (HPLC) solid |
M0443 |
Nonselective |
| Nomifensine maleate salt |
N1530 |
Nonselective |
| Trazodone hydrochloride >99 % (HPLC) powder |
T6154 |
Nonselective |
| Trimipramine maleate salt >99 % (TLC) powder |
T3146 |
Nonselective |
| Reboxetine mesylate >96 % (HPLC) solid |
R6527 |
Norepinephrine |
| (R)-Tomoxetine hydrochloride solid |
T7947 |
Norepinephrine |
| Citalopram hydrobromide |
C7861 |
Serotonin |
| Fluvoxamine maleate solid |
F2802 |
Serotonin |
| LY-367,265 |
L2411 |
Serotonin |
| Nefazodone hydrochloride ³99 % (HPLC) solid |
N5536 |
Serotonin |
| Reserpine |
R0875 |
Vesicular |
| Cholinergics |
|
back to top |
| Product Name |
Product # |
Specificity |
| Agonists |
|
|
| Acetylcholine chloride min. 99 % (TLC) solid |
A6625 |
Endogenous |
| (+)-Nicotine (+)-di-p-toluoyltartrate salt min. 99 % (TLC) powder |
N9765 |
Less active enantiomer |
| Arecaidine propargyl ester hydrobromide solid |
A-140 |
Muscarinic |
| Carbamyl-b-methylcholine chloride min. 99 % (TLC) crystalline |
C5259 |
Muscarinic |
| (+)-cis-Dioxolane solid |
C-008 |
Muscarinic |
| (+)-Muscarine chloride approx. 95 % (TLC) powder |
M6532 |
Muscarinic |
| Muscarinic Toxin-1 from Dendroaspis angusticeps venom ³98 % (SDS-PAGE) Lyophilized powder |
M9308 |
Muscarinic |
| Muscarinic Toxin-2 from Dendroaspis angusticeps venom min. 98 % (SDS-PAGE) Lyophilized powder |
M8058 |
Muscarinic |
| Oxotremorine M solid |
O-100 |
Muscarinic |
| Pilocarpine hydrochloride min. 99 % (titration) powder |
P6503 |
Muscarinic |
| Pilocarpine nitrate salt min. 99 % (TLC) powder |
P6628 |
Muscarinic |
| CDD 0097 hydrochloride solid |
C-258 |
Muscarinic, M1 |
| McN-A-343 min. 99 % (TLC) powder |
C7041 |
Muscarinic, M1 |
| Oxotremorine min. 95 % (TLC) liquid |
O6876 |
Muscarinic, M2, M4 |
| Oxotremorine sesquifumarate salt min. 98 % (TLC) powder |
O9126 |
Muscarinic, M2, M4 |
| ABT-418 hydrochloride >98 % (HPLC) solid |
A6476 |
Nicotinic |
| Acetylthiocholine chloride min. 99 % (TLC) powder |
A5626 |
Nicotinic |
| Acetylthiocholine iodide min. 98 % (TLC) powder |
A5751 |
Nicotinic |
| (±)-Anabasine min. 90 % (TLC) liquid |
A5656 |
Nicotinic |
| (+)-Anatoxin-A fumarate salt solid |
A-224 |
Nicotinic |
| 1,1-Dimethyl-4-phenylpiperazinium iodide min. 99 % (TLC or titration) powder |
D5891 |
Nicotinic |
| (+)-Epibatidine hydrochloride min. 99 % (TLC) powder |
E1020 |
Nicotinic |
| (±)-Epibatidine dihydrochloride min. 99 % (TLC) powder |
E1145 |
Nicotinic |
| Epiboxidine hydrochloride solid |
E-152 |
Nicotinic |
| a-Lobeline hydrochloride approx. 95 % (HPLC) powder |
L4376 |
Nicotinic |
| Methylcarbamylcholine chloride solid |
M-140 |
Nicotinic |
| (-)-Nicotine min. 99 % (GC) liquid |
N3876 |
Nicotinic |
| (-)-Nicotine hemisulfate salt min. 95 % (TLC) approx. 40 % (w/v) in water (nicotine free base content) |
N1019 |
Nicotinic |
| (-)-Nicotine hydrogen tartrate salt min. 98 % (TLC) powder |
N5260 |
Nicotinic |
| (±)-Nicotine min. 99 % (TLC) liquid |
N0267 |
Nicotinic |
| (±)-Nornicotine min. 99 % (TLC) liquid |
N3018 |
Nicotinic |
| RJR-2403 hemigalactarate min. 99 % (HPLC) powder |
R-130 |
Nicotinic |
| RJR-2429 dihydrochloride solid |
R-131 |
Nicotinic (neuromuscular) |
| A-85380 dihydrochloride solid |
A-251 |
Nicotinic (neuronal) |
| DBO-83 solid |
D7938 |
Nicotinic (neuronal) |
| Ivermectin |
I8898 |
Nicotinic, a7 modulator |
| O-Acetyl-L-carnitine hydrochloride min. 99 % (titration) powder |
A6706 |
Nonselective |
| Acetyl-b-methylcholine chloride min. 98 % (TLC) powder |
A2251 |
Nonselective |
| Arecoline hydrobromide min. 99 % (HPLC) powder |
A6134 |
Nonselective |
| Carbamoylcholine chloride min. 98 % (TLC) min. 99 % (titration) crystalline |
C4382 |
Nonselective |
| Antagonists |
|
|
| Aminobenztropine solid |
A-138 |
Muscarinic |
| Atropine min. 99 % (TLC) powder |
A0132 |
Muscarinic |
| Atropine sulfate salt hydrate min. 97 % (TLC) crystalline |
A0257 |
Muscarinic |
| Atropine methyl bromide min. 99 % (TLC) powder |
A6883 |
Muscarinic |
| Atropine methyl nitrate min. 99 % (TLC) powder |
A0382 |
Muscarinic |
| Benztropine mesylate salt min. 99 % (TLC) powder |
B8262 |
Muscarinic |
| Dicyclomine hydrochloride min. 99 % (TLC) powder |
D7909 |
Muscarinic |
| DL-Homatropine hydrobromide min. 98 % (TLC) powder |
H0126 |
Muscarinic |
| L-Hyoscyamine min. 98 % (TLC) powder |
H9002 |
Muscarinic |
| L-Hyoscyamine hydrobromide min. 99 % (TLC) powder |
H9253 |
Muscarinic |
| Ipratropium bromide min. 99 % (TLC) powder |
I1637 |
Muscarinic |
| Muscarinic Toxin-3 from Dendroaspis angusticeps venom ³98 % (SDS-PAGE) Lyophilized powder |
M5933 |
Muscarinic |
| Orphenadrine hydrochloride |
O3752 |
Muscarinic |
| Oxybutynin chloride min. 99 % (TLC) powder |
O2881 |
Muscarinic |
| Propantheline bromide min. 98 % (TLC) powder |
P8891 |
Muscarinic |
| (±)-Quinuclidinyl benzilate powder |
C-002 |
Muscarinic |
| (-)-Scopolamine hydrobromide trihydrate min. 98 % (TLC) powder |
S1875 |
Muscarinic |
| (-)-Scopolamine hydrochloride min. 90 % (TLC) powder |
S1013 |
Muscarinic |
| (-)-Scopolamine N-butyl bromide min. 99 % (TLC) powder |
S7882 |
Muscarinic |
| (-)-Scopolamine methyl bromide min. 99 % (HPLC) powder |
S8502 |
Muscarinic |
| (-)Scopolamine methyl nitrate |
S2250 |
Muscarinic |
| DL-Trihexyphenidyl hydrochloride solid |
T1516 |
Muscarinic |
| Pirenzepine dihydrochloride min. 98 % (TLC) powder |
P7412 |
Muscarinic, M1 |
| Telenzepine dihydrochloride solid |
T-122 |
Muscarinic, M1 |
| Gallamine triethiodide min. 98 % (TLC) powder |
G8134 |
Muscarinic, M2 |
| Imperialine 97 % solid |
I7779 |
Muscarinic, M2 |
| Methoctramine tetrahydrochloride solid |
M-105 |
Muscarinic, M2 |
| (+)-Himbacine approx. 98 % (GC) powder |
H4904 |
Muscarinic, M2, M4 |
| 4-Diphenylacetoxy-N-(2-chloroethyl)piperidine hydrochloride solid |
D-142 |
Muscarinic, M3 (Irreversible) |
| p-Fluorohexahydro-sila-difenidol hydrochloride solid |
H-127 |
Muscarinic, M3 > M1 > M2 |
| 4-Diphenylacetoxy-N-methylpiperidine methiodide powder |
D-104 |
Muscarinic, M3 > M1 = M4 = M5 > M2 |
| Tropicamide solid |
T9778 |
Muscarinic, M4 |
| a-Cobratoxin from Naja naja kaouthia |
C6903 |
Nicotinic |
| Condelphine 95 % solid |
C2108 |
Nicotinic |
| a-Conotoxin Im I min. 97 % (HPLC) |
C2461 |
Nicotinic |
| Delcorine min. 97 % (TLC) solid |
D6939 |
Nicotinic |
| Delsoline min. 97 % (TLC) solid |
D7064 |
Nicotinic |
| Deltaline min. 97 % (TLC) solid |
D7189 |
Nicotinic |
| Dihydro-b-erythroidine hydrobromide solid |
D-149 |
Nicotinic |
| Diplacine min. 98 % solid |
D7564 |
Nicotinic |
| Diquine min. 98 % solid |
D7689 |
Nicotinic |
| Fluorocurarine chloride from (From the plant Vinca erecta, from the family Apocynaceae) min. 97 % (TLC) solid |
F6301 |
Nicotinic |
| Hexamethonium bromide |
H0879 |
Nicotinic |
| Hexamethonium chloride solid (hygroscopic) |
H2138 |
Nicotinic |
| Karakoline 97 % solid |
K4262 |
Nicotinic |
| Mecamylamine hydrochloride |
M9020 |
Nicotinic |
| Methyllycaconitine citrate from Delphinium brownii seeds solid |
M-168 |
Nicotinic |
| MG 624 min. 98 % |
M3184 |
Nicotinic |
| Pancuronium bromide |
P1918 |
Nicotinic |
| Pempidine tartrate min. 98 % (TLC) |
P5114 |
Nicotinic |
| Pentolinium di[L(+)-tartrate] |
P3520 |
Nicotinic |
| Quirestine min. 99.5 % (TLC) |
Q0255 |
Nicotinic |
| Temechine hydrobromide min. 99.5 % (TLC) |
T4569 |
Nicotinic |
| Tempidine min. 98 % (TLC) |
T4694 |
Nicotinic |
| Tempidol hydrochloride min. 98 % (TLC) |
T4944 |
Nicotinic |
| Tempoxime hydrochloride min. 98 % (TLC) |
T4819 |
Nicotinic |
| N,N,N-Trimethyl-1-(4-trans-stilbenoxy)-2-propylammonium iodide |
T6692 |
Nicotinic |
| Tetraethylammonium chloride min. 98 % (titration) |
T2265 |
Nicotinic |
| Decamethonium bromide crystalline |
D1260 |
Nicotinic (neuromuscular partial agonist) |
| a-Bungarotoxin from Bungarus multicinctus solid |
T3019 |
Nicotinic (neuromuscular) |
| Succinylcholine chloride dihydrate min. 98 % solid |
S8251 |
Nicotinic (neuromuscular) |
| (+)-Tubocurarine chloride hydrate |
T2379 |
Nicotinic (neuromuscular) |
| RJR-2429 dihydrochloride solid |
R-131 |
Nicotinic (neuronal) |
| Bromoacetylcholine bromide solid |
B-121 |
Nicotinic alkylating agent |
| a-Bungarotoxin–FITC labeled from Bungarus multicinctus |
T9641 |
Nicotinic probe |
| Enzyme inhibitors |
|
|
| 9-Amino-1,2,3,4-tetrahydroacridine hydrochloride |
A3773 |
Acetylcholinesterase |
| 1,5-Bis(4-allyldimethylammoniumphenyl)pentan-3-one dibromide |
A9013 |
Acetylcholinesterase |
| Diisopropyl fluorophosphate |
D0879 |
Acetylcholinesterase |
| Edrophonium chloride |
E3256 |
Acetylcholinesterase |
| Eserine |
E8375 |
Acetylcholinesterase |
| Eserine hemisulfate salt |
E8625 |
Acetylcholinesterase |
| |
F3918 |
Acetylcholinesterase |
| Galanthamine hydrobromide from Lycoris sp. |
G1660 |
Acetylcholinesterase |
| (-)-Huperzine A |
H5902 |
Acetylcholinesterase |
| (±)-Huperzine A |
H5777 |
Acetylcholinesterase |
| Neostigmine bromide min. 98 % (TLC and titration) powder |
N2001 |
Acetylcholinesterase |
| Neostigmine methyl sulfate |
N2126 |
Acetylcholinesterase |
| Pyridostigmine bromide |
P9797 |
Acetylcholinesterase |
| Acetylethylcholine mustard hydrochloride solid |
C-001 |
Choline acetyl-transferase |
| Bromoacetylcholine bromide solid |
B-121 |
Choline acetyl-transferase |
| 2-(a-Naphthoyl)ethyltrimethylammonium iodide min. 97 % (HPLC) solid |
N7906 |
Choline acetyl-transferase |
| Enzyme substrates |
|
|
| Acetylthiocholine chloride min. 99 % (TLC) powder |
A5626 |
Acetylcholinesterase |
| Acetylthiocholine iodide min. 98 % (TLC) powder |
A5751 |
Acetylcholinesterase |
| Choline bitartrate approx. 99 % |
C1629 |
Choline acetyl-transferase |
| Choline bromide approx. 99 % |
C1754 |
Choline acetyl-transferase |
| Choline chloride min. 98 % |
C1879 |
Choline acetyl-transferase |
| Enzymes |
|
|
| Acetylcholinesterase Electrophorus electricus (electric eel) Type III Aqueous solution ³1,000 units/mg protein |
C2629 |
|
| Acetylcholinesterase Electrophorus electricus (electric eel) Type V-S Lyophilized powder ³1,000 units/mg protein |
C2888 |
|
| Acetylcholinesterase bovine erythrocytes Type XII-S Lyophilized powder 0.25-1.0 unit/mg solid |
C5021 |
|
| Acetylcholinesterase human Lyophilized powder Recombinant min. 2,000 units/mg protein (Lowry) |
C1682 |
|
| Choline Acetyltransferase from human placenta suitable for assay of choline Ammonium sulfate suspension min. 20 units/mg protein (biuret) |
C2898 |
|
| Other |
|
|
| Dithiobiuret 97 % solid |
D3190 |
Inhibitor of ACh release |
| WB64 solid |
W4761 |
Muscarinic M2 Ligand |
| Receptors |
|
|
| M1 Muscarinic Receptor human recombinant, expressed in CHO cells Membrane suspension |
M-194 |
|
| M2 Muscarinic Receptor human recombinant, expressed in CHO cells Membrane suspension |
M4560 |
|
| M3 Muscarinic Receptor human recombinant, expressed in Sf 9 cells Membrane suspension |
M-176 |
|
| Release enhancers |
|
|
| Linopirdine solid |
L-134 |
|
| Release inhibitors |
|
|
| b-Bungarotoxin from Bungarus multicinctus |
T5644 |
|
| Storage inhibitors |
|
|
| L(–)-Vesamicol hydrochloride solid |
V-101 |
|
| (±)-Vesamicol hydrochloride >98 % solid |
V-100 |
|
| Transport inhibitors |
|
|
| Acetylethylcholine mustard hydrochloride solid |
C-001 |
|
| Hemicholinium-3 solid |
H-108 |
|
| Dopaminergics |
|
back to top |
| Product Name |
Product # |
Specificity |
| Agonists |
|
|
| A-68930 hydrochoride min. 98 % (HPLC) solid |
A8852 |
D1 |
| N-Allyl-(±)-SKF-38393 hydrobromide solid |
S-168 |
D1 |
| Chloro-APB hydrobromide solid |
C-130 |
D1 |
| (±)-6-Chloro-PB hydrobromide solid |
S-143 |
D1 |
| Dihydrexidine hydrochloride solid |
D5814 |
D1 |
| Fenoldopam hydrobromide min. 98 % |
F6800 |
D1 |
| SKF-75670 hydrobromide >98 % (HPLC) |
S2941 |
D1 |
| SKF-83565 hydrobromide >98 % (HPLC) solid |
S3191 |
D1 |
| SKF 83959 hydrobromide >98 % (HPLC) solid |
S2816 |
D1 |
| SKF-89145 hydrobromide >98 % (HPLC) solid |
S3316 |
D1 |
| SKF-89626 hydrobromide >98 % (HPLC) solid |
S3066 |
D1 |
| Deoxyepinephrine hydrochloride 95-98 % solid |
D5886 |
D1, D2 |
| Pergolide mesylate salt min. 98 % solid |
P8828 |
D1, D2 |
| A-77636 hydrochloride min. 97 % solid |
A-255 |
D1, D5 |
| R(+)-6-Bromo-APB hydrobromide solid |
B-135 |
D1, D5 |
| (R)-(+)-SKF-38393 hydrochloride >96 % solid |
S-101 |
D1, D5 |
| (±)-SKF-38393 hydrochloride crystalline |
D-047 |
D1, D5 |
| R(+)-SKF-81297 hydrobromide solid |
S-179 |
D1, D5 |
| R(+)-SKF-82957 hydrobromide solid |
S-178 |
D1, D5 |
| B-HT 920 dihydrochloride solid |
B-162 |
D2 |
| R(+)-3-(3-Hydroxyphenyl)-N-propylpiperidine hydrochloride solid |
P-102 |
D2 |
| (S)-(-)-3-(3-Hydroxyphenyl)-N-propylpiperidine hydrochloride >98 % solid |
P-103 |
D2 |
| S(-)-Lisuride solid |
L-122 |
D2 |
| (±)-2-(N-Phenethyl-N-propyl)amino-5-hydroxytetralin hydrochloride solid |
P-105 |
D2 |
| R(-)-Propylnorapomorphine hydrochloride solid |
D-027 |
D2 |
| Quinelorane dihydrochloride crystalline |
Q-110 |
D2 |
| (±)-Quinpirole dihydrochloride solid |
Q-111 |
D2 |
| R(+)-Terguride solid |
T-165 |
D2 |
| S(-)-Terguride hydrogen maleate solid |
T-134 |
D2 |
| R(-)-2,10,11-Trihydroxyaporphine hydrobromide >97 % Small crystals |
D-029 |
D2 |
| R(-)-2,10,11-Trihydroxy-N-propyl-noraporphine hydrobromide solid |
D-030 |
D2 |
| Dihydroergotamine methanesulfonate salt powder |
D2763 |
D2 (partial) |
| PPHT-fluorescein acetate solid |
P-138 |
D2 fluorescent probe |
| R(-)-N-Allylnorapomorphine hydrobromide solid |
D-042 |
D2, D1 |
| |
D-004 |
D2, D1 |
| R-(-)-Apomorphine hydrochloride hemihydrate min. 99 % |
A4393 |
D2, D1 |
| 2-Bromo-a-ergocryptine methanesulfonate salt solid |
B2134 |
D2, D3 |
| (–)-Quinpirole hydrochloride solid |
Q-102 |
D2, D3 |
| BP897 >98 % (HPLC) |
B9308 |
D3 Partial |
| FAUC 73 liquid |
F1041 |
D3 |
| R(+)-7-Hydroxy-DPAT hydrobromide >98 % solid |
H-168 |
D3 |
| cis-8-Hydroxy-3-(n-propyl)-1,2,3a,4,5,9b-hexahydro-1H-benz[e]indole hydrobromide min. 98 % (HPLC) solid |
P0618 |
D3 |
| (+)-PD 128,907 hydrochloride >97 % solid |
P-183 |
D3 |
| (±)-PD 128,907 hydrochloride solid |
P-216 |
D3 |
| Piribedil maleate salt |
P9233 |
D3 |
| (±)-7-Hydroxy-2-(di-n-propylamino)tetralin hydrobromide solid |
H8653 |
D3 > D2 |
| PD 168,077 maleate salt powder |
P-233 |
D4 |
| N-[2-(4-(4-Chlorophenyl)piperazin-1-yl)ethyl]-3-methoxybenzamide solid |
C7230 |
D4 |
| Dopamine hydrochloride solid |
H8502 |
Endogenous (nonselective) |
| S(-)-6-Bromo-APB hydrobromide solid |
B-136 |
Less active enantiomer |
| S-(-)-SKF-38393 hydrochloride solid |
S-102 |
Less active enantiomer |
| (±)-2-Amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene hydrobromide solid |
D-002 |
Nonselective |
| R(-)-Apocodeine hydrochloride solid |
D-003 |
Nonselective |
| (±)-2-Dipropylamino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene hydrobromide solid |
D-012 |
Nonselective |
| Ergocornine >95 % solid |
E-131 |
Nonselective |
| Ergocristine |
E-140 |
Nonselective |
| a-Ergocryptine |
E5625 |
Nonselective |
| m-Tyramine hydrochloride solid |
D-017 |
Nonselective |
| Maleic acid 99 % |
M-153 |
Nonselective |
| R(–)-Norapomorphine hydrobromide solid |
D-040 |
Nonselective |
| Tyramine solid |
T7255 |
Nonselective |
| Tyramine hydrochloride min. 99 % |
T2879 |
Nonselective |
| Antagonists |
|
|
| LE 300 solid |
L8401 |
D1 |
| Droperidol |
D1414 |
D1, D2 |
| cis-(Z)-Flupenthixol dihydrochloride |
F-114 |
D1, D2 |
| Fluphenazine dihydrochloride |
F4765 |
D1, D2 |
| Perphenazine |
P6402 |
D1, D2 |
| Thioridazine hydrochloride min. 99 % |
T9025 |
D1, D2 |
| cis-Thiothixene |
T0780 |
D1, D2 |
| Trifluoperazine dihydrochloride min. 99 % powder |
T8516 |
D1, D2 |
| Trifluperidol hydrochloride solid |
T-103 |
D1, D2 |
| R(-)-SCH-12679 maleate salt solid |
S-159 |
D1, D5 |
| R(+)-SCH-23390 hydrochloride solid |
D-054 |
D1, D5 |
| (±)-SKF-83566 hydrochloride solid |
S-110 |
D1, D5 |
| Chlorpromazine hydrochloride |
C8138 |
D2 |
| Chlorprothixene hydrochloride |
C1671 |
D2 |
| S(-)-Eticlopride hydrochloride |
E-101 |
D2 |
| (S)-(-)-IBZM oil |
I-139 |
D2 |
| L-741,626 solid |
L-135 |
D2 |
| N-Methylspiperone hydrochloride solid |
S-128 |
D2 |
| Metoclopramide hydrochloride solid |
M0763 |
D2 |
| Octoclothepin maleate salt solid |
O-111 |
D2 |
| Pimozide |
P1793 |
D2 |
| Prochlorperazine dimaleate salt |
P9178 |
D2 |
| Promazine hydrochloride |
P6656 |
D2 |
| Propionylpromazine hydrochloride |
P7780 |
D2 |
| S(-)-Raclopride (+)-tartrate salt >97 % solid |
R-121 |
D2 |
| Risperidone solid |
R-118 |
D2 |
| Spiperone solid |
S7395 |
D2 |
| ST-148 solution |
S1441 |
D2 |
| (S)-(-)-Sulpiride |
S7771 |
D2 |
| (±)-Sulpiride powder |
S8010 |
D2 |
| Triflupromazine hydrochloride |
T2896 |
D2 |
| S(+)-Propylnorapomorphine hydrochloride solid |
D-041 |
D2 (limbic selective) |
| S(-)-BZM Semisolid |
B-146 |
D2 (precursor to 125I-BZM) |
| S(+)-O-Desmethylraclopride hydrobromide solid |
D-204 |
D2 (precursor to radiolabeled raclopride) |
| N-(p-Isothiocyanatophenethyl)spiperone hydrochloride |
N-140 |
D2 alkylating agent |
| (+)-Butaclamol hydrochloride solid |
D-033 |
D2, D1 |
| Fluspirilene Amorphous solid |
F-100 |
D2, D1 |
| Haloperidol powder |
H1512 |
D2, D1 |
| Tiapride hydrochloride |
T0410 |
D2, D3 |
| Loxapine succinate salt solid |
L-106 |
D2, D4 |
| Domperidone solid |
D-122 |
D3, D2 (peripheral) |
| S(-)-DS 121 hydrochloride solid |
D-206 |
D3 (autoreceptor) |
| GR 103691 >98 % (HPLC) solid |
G0544 |
D3 |
| GR 218231 >98 % (HPLC) solid |
G9168 |
D3 |
| (S)-Nafadotride tartrate >98 % (HPLC) solid |
N3535 |
D3 |
| U-99194A maleate salt solid |
U-116 |
D3 |
| L-745,870 hydrochloride solid |
L-131 |
D4 |
| L-750,667 trihydrochloride solid |
L-133 |
D4 |
| RBI 257 maleate salt solid |
R-123 |
D4 |
| U-101958 maleate salt solid |
U-115 |
D4 |
| Clozapine |
C6305 |
D4 > D2, D3 |
| (-)-Butaclamol hydrochloride solid |
D-034 |
Less active enantiomer |
| trans-(E)-Flupenthixol dihydrochloride solid |
F-115 |
Less active enantiomer |
| |
S-113 |
Less active enantiomer |
| Acetopromazine maleate salt |
A6908 |
Nonselective |
| S(+)-Apomorphine hydrochloride Small crystals |
D-043 |
Nonselective |
| |
E1004 |
Nonselective alkylating agent |
| Enzyme inhibitors |
|
|
| Benserazide hydrochloride min. 98 % (TLC) solid |
B7283 |
L-Amino acid decarboxylase |
| S(-)-Carbidopa: HBC complex |
C-164 |
L-Amino acid decarboxylase |
| (±)-3-(3,4-Dihydroxyphenyl)-2-methyl-DL-alanine |
M7277 |
L-Amino acid decarboxylase |
| 3-Hydroxybenzylhydrazine dihydrochloride 95-98 % (TLC) |
H9382 |
L-Amino acid decarboxylase |
| 3,5-Dinitrocatechol solid |
D-131 |
Catechol-O-methyltransferase |
| Ro 41-0960 solid |
R-108 |
Catechol-O-methyltransferase |
| R-(-)-Deprenyl hydrochloride solid |
M-003 |
Monoamine oxidase |
| Hydralazine hydrochloride |
H1753 |
Monoamine oxidase |
| Hydroxylamine hydrochloride min. 99 % (titration) |
H9876 |
Monoamine oxidase |
| Hydroxylamine sulfate salt min. 99 % (titration) |
H0127 |
Monoamine oxidase |
| Iproniazid phosphate salt |
I7627 |
Monoamine oxidase |
| N-Methyl-N-propargyl-3-(2,4-dichlorophenoxy)propylamine hydrochloride |
M3778 |
Monoamine oxidase |
| Nialamide min. 95 % (HPLC) |
N1392 |
Monoamine oxidase |
| Pargyline hydrochloride |
P8013 |
Monoamine oxidase |
| Phenelzine sulfate salt |
P6777 |
Monoamine oxidase |
| trans-2-Phenylcyclopropylamine hemisulfate salt |
P1761 |
Monoamine oxidase |
| trans-2-Phenylcyclopropylamine hydrochloride |
P8511 |
Monoamine oxidase |
| Quinacrine dihydrochloride min. 90 % |
Q3251 |
Monoamine oxidase |
| Ro 41-1049 hydrochloride solid |
R-107 |
Monoamine oxidase |
| Ro 16-6491 hydrochloride solid |
R-106 |
Monoamine oxidase |
| Kojic acid |
K3125 |
Tyrosinase |
| 3-Iodo-L-tyrosine |
I8250 |
Tyrosine hydroxylase |
| a-Methyl-L-tyrosine |
M8131 |
Tyrosine hydroxylase |
| |
M7628 |
Tyrosine hydroxylase |
| a-Methyl-DL-tyrosine methyl ester hydrochloride min. 98 % (TLC) |
M3281 |
Tyrosine hydroxylase |
| Enzymes |
|
|
| Catechol-O-methyl Transferase porcine liver Lyophilized powder min. 1,000 units/mg protein |
C1897 |
|
| L-Phenylalanine decarboxylase Streptococcus faecalis Dried cells min. 5 units/g solid |
P9957 |
|
| Tyrosinase mushroom ³2,000 units/mg solid |
T7755 |
|
| Metabolites |
|
|
| 3,4-Dihydroxyphenylacetic acid |
D9128 |
|
| Homovanillic acid |
H1252 |
|
| 3-Hydroxy-4-methoxyphenethylamine hydrochloride |
H3132 |
|
| 3-Methoxytyramine hydrochloride min. 96 % |
M4251 |
|
| Neurotoxins |
|
|
| 6-Hydroxydopamine hydrobromide |
H-116 |
|
| 6-Hydroxydopamine hydrobromide min. 90 % (HPLC) solid |
H8523 |
|
| 6-Hydroxydopamine hydrochloride >97 % (titration) crystalline |
H4381 |
|
| 1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine hydrochloride solid |
M-103 |
|
| 1-Methyl-4-phenyl-2,3-dihydropyridinium perchlorate >98 % solid |
D-051 |
|
| 1-Methyl-4-phenylpyridinium iodide solid |
D-048 |
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride |
M0896 |
|
| Others |
|
|
| N-Methyl-(R)-salsolinol hydrobromide min. 95 % (HPLC) solid |
M3690 |
Neurotoxin |
| Precursors |
|
|
| 3,4-Dihydroxy-D-phenylalanine |
D9378 |
Less active enantiomer |
| D-Tyrosine min. 98 % (TLC) |
T3254 |
Less active enantiomer |
| N-Acetyldopamine monohydrate |
A8762 |
|
| 3,4-Dihydroxy-DL-phenylalanine |
D9503 |
|
| |
D-009 |
|
| L-3,4-Dihydroxyphenylalanine methyl ester hydrochloride solid |
D1507 |
|
| L-Tyrosine min. 98 % (TLC) |
T3754 |
|
| L-Tyrosine disodium salt min. 98 % (TLC) powder |
T2269 |
|
| L-Tyrosine hydrochloride min. 98 % (TLC) |
T2006 |
|
| Receptors |
|
|
| D1 Dopamine Receptor human recombinant, expressed in Sf9 cells |
D-178 |
|
| D3 Dopamine Receptor rat recombinant, expressed in Escherichia coli Membrane suspension |
D-181 |
|
| D3 Dopamine Receptor human recombinant, expressed in CCLI-3 cells Membrane suspension |
D-152 |
|
| D2long Dopamine Receptor human recombinant, expressed in Sf9 cells Membrane suspension |
D-180 |
|
| D4,2 Dopamine Receptor human recombinant, expressed in CHO cells Non-viable cells |
D-177 |
|
| Releasers |
|
|
| Amantadine hydrochloride |
A1260 |
|
| Phentermine hydrochloride |
P8653 |
|
| Transport inhibitors |
|
|
| Amfonelic acid powder |
D-044 |
|
| BTCP hydrochloride solid |
B-138 |
|
| Bupropion hydrochloride solid |
B-102 |
|
| b-CFT Naphthalenesulfonate solid |
C-124 |
|
| 4'-Chloro-3a-(diphenylmethoxy)tropane hydrochloride solid |
C-207 |
|
| Cocaine hydrochloride |
C5776 |
|
| Cocaine free base |
C8912 |
|
| 4',4''-Difluoro-3a-(diphenylmethoxy)tropane hydrochloride solid |
D-205 |
|
| GBR 12909 dihydrochloride solid |
D-052 |
|
| GBR 12935 dihydrochloride min. 99 % (TLC) powder |
G9659 |
|
| GYKI 52895 solid |
G-120 |
|
| Nomifensine maleate salt |
N1530 |
|
| Reserpine |
R0875 |
Vesicular |
| Transporters |
|
|
| Dopamine Transporter human recombinant, expressed in CHO cells Membrane suspension |
D-209 |
|
| Excitatory Amino Acids |
|
back to top
|
| Product Name |
Product # |
Specificity |
| Agonists, Ionotropic |
|
|
| Aniracetam approx. 98 % |
A9950 |
AMPA potentiator |
| Cyclothiazide |
C9847 |
AMPA potentiator |
| IDRA 21 min. 98 % |
I5773 |
AMPA potentiator |
| L-(+)-2-Amino-6-phosphonohexanoic acid min. 98 % (HPLC) |
A5352 |
AMPA/kainate |
| (S)-5-Fluorowillardiine |
F2417 |
AMPA/kainate |
| (R)-AMPA solid |
A-266 |
Less active enantiomer |
| (S)-AMPA min. 98 % |
A0326 |
|
| (±)-AMPA solid |
A6816 |
|
| (±)-AMPA hydrobromide solid |
G-017 |
|
| 2,6-Difluoro-4-[2-(phenylsulfonylamino)ethylthio]phenoxyacetamide >98 % (HPLC) |
D8941 |
|
| Quisqualic acid solid |
Q2128 |
|
| S(-)-Willardiine solid |
W-105 |
AMPA/kainate |
| IEM-1460 solid |
I0154 |
Ca2+ permeable APMA receptors |
| Dihydrokainic acid >99 % solid |
D1064 |
Glutamate receptor blocker |
| ATPO solid |
A7845 |
mGluR1-4 |
| ATPA solid |
A-263 |
|
| Domoic acid approx. 90 % solid |
D6152 |
|
| (S)-5-Iodowillardiine solid |
W-110 |
|
| Kainic acid >99 % |
K0250 |
|
| CR 2249 |
N2034 |
Glycine potentiator |
| 1-Aminocyclopropanecarboxylic acid ³98 % (TLC) |
A3903 |
Glycine site |
| 1-Aminocyclopropanecarboxylic acid hydrochloride 97 % |
A0430 |
Glycine site |
| D-Serine min. 98 % (TLC) |
S4250 |
Glycine site |
| D-Cycloserine synthetic |
C3909 |
Glycine site partial agonist |
| Putrescine dihydrochloride min. 98 % (TLC) |
P7505 |
Polyamine site |
| Spermidine min. 98 % (GC) |
S2626 |
Polyamine site |
| Spermidine trihydrochloride min. 98 % (TLC) |
S2501 |
Polyamine site |
| Spermine approx. 97 % |
S3256 |
Polyamine site |
| Spermine tetrahydrochloride min. 95 % (TLC) |
S2876 |
Polyamine site |
| L-Cysteine hydrochloride monohydrate min. 98 % (TLC) |
C7880 |
|
| Ibotenic acid approx. 95 % solid |
I2765 |
|
| N-Methyl-D-aspartic acid min. 98 % (titration) solid |
M3262 |
|
| cis-2,3-Piperidinedicarboxylic acid |
P8782 |
|
| Quinolinic acid 99 % |
"P6,320-4" |
|
| Agonists, Metabotropic |
|
|
| (S)-3,5-Dihydroxyphenylglycine |
D3689 |
mGluR1 |
| (+)-3-Hydroxyphenylglycine powder |
H-173 |
mGluR1, mGluR5 |
| (±)-3-Hydroxyphenylglycine powder |
H-174 |
mGluR1, mGluR5 |
| (2S,1'S,2'S)-2-(Carboxycyclopropyl)glycine solid |
C-237 |
mGluR2, mGluR3 |
| N-Acetyl-Asp-Glu min. 97 % (TLC) powder |
A5930 |
mGluR3 |
| PBDA >95 % (NMR) liquid |
P2238 |
mGluR3 |
| L-(+)-2-Amino-4-phosphonobutyric acid Optical purity: ³95% (HPLC, Marfey's reagent) |
A7929 |
mGluR4, mGluR6, mGluR7, mGluR8 |
| O-Phospho-L-serine |
P0878 |
mGluR4, mGluR6 |
| trans-(1S,3R)-ACPD >97 % solid |
A-182 |
Nonselective |
| trans-(±)-ACPD solid |
A-155 |
Nonselective |
| Agonists, Nonselective |
|
|
| D-Aspartic acid min. 99 % (TLC) |
A8881 |
Less active enantiomer |
| D-Glutamic acid min. 99 % (TLC) |
G1001 |
Less active enantiomer |
| L-Aspartic acid min. 98 % (TLC) |
A9256 |
|
| L-Aspartic acid hemimagnesium salt hydrate min. 98 % (TLC) |
A9506 |
|
| L-Aspartic acid potassium salt min. 98 % (TLC) |
A6558 |
|
| L-Aspartic acid sodium salt monohydrate min. 98 % (TLC) |
A6683 |
|
| L-Cysteinesulfinic acid |
C4418 |
|
| Glutamate, Caged solid |
G3291 |
|
| L-Glutamic acid min. 99 % (TLC) |
G1251 |
|
| L-Glutamic acid hydrochloride min. 98 % (TLC) |
G2128 |
|
| L-Glutamic acid potassium salt monohydrate min. 99 % (TLC) powder |
G1501 |
|
| L-Glutamic acid sodium salt hydrate min. 99 % (TLC) powder |
G1626 |
|
| L-Glutamic acid diethyl ester hydrochloride |
G9378 |
|
| L-Homocysteic acid |
H9633 |
|
| D-Homocysteinesulfinic acid min. 98 % (TLC) |
H3899 |
|
| Antagonists, Ionotropic |
|
|
| GYKI 52466 hydrochloride solid |
G-119 |
Allosteric |
| CX546 solid |
C-271 |
|
| 1-Naphthylacetyl spermine trihydrochloride >97 % solid |
N-193 |
|
| CNQX solid |
C-127 |
|
| CNQX disodium salt solid |
C-239 |
|
| CNQX-HBC complex |
C-169 |
|
| DNQX approx. 98 % |
D0540 |
|
| NBQX solid |
N-171 |
|
| NBQX disodium salt solid |
N-183 |
|
| g-D-Glutamylaminomethylsulfonic acid solid |
G-111 |
|
| (2S,4R)-4-Methylglutamic acid solid |
G-137 |
|
| NS 102 solid |
N-179 |
|
| S(+)-Methadone hydrochloride solid |
M-150 |
Allosteric |
| 7-Chlorokynurenic acid solid |
C-121 |
Glycine site |
| 5,7-Dichlorokynurenic acid solid |
D-138 |
Glycine site |
| 6,7-Dichloroquinoxaline-2,3-dione |
D-133 |
Glycine site |
| R(+)-HA-966 solid |
H-130 |
Glycine site |
| Kynurenic acid min. 98 % |
K3375 |
Glycine site |
| L-701,324 |
L0258 |
Glycine site |
| MDL 105,519 solid |
M-216 |
Glycine site |
| (±)-Ketamine hydrochloride solid |
K2753 |
Ion channel blocker |
| (+)-MK-801 hydrogen maleate solid |
M-107 |
Ion channel blocker |
| N-(3,3-Diphenylpropyl)glycinamide >98 % (HPLC) |
D8816 |
Ion channel blocker |
| Phencyclidine hydrochloride |
P3029 |
Ion channel blocker |
| (-)-MK-801 hydrogen maleate solid |
M-108 |
Less active enantiomer |
| Felbamate |
F0778 |
NMDAR2B |
| Ro 25-6981 hydrochloride |
R7150 |
NMDAR2B |
| Ro 8-4304 solid |
R8900 |
NMDAR2B |
| Arcaine sulfate salt |
A0384 |
Polyamine site |
| Ifenprodil tartrate salt |
I2892 |
Polyamine site |
| Philanthotoxin 433 tris(trifluoroacetate) salt >99 % solid |
P-207 |
Polyamine site |
| [Glu3,4,7,10,14]-Conantokin G >90 % (HPLC) |
C1733 |
Polyamine-like action |
| (±)-2-Amino-4-phosphonobutyric acid solid |
A1910 |
|
| D(-)-2-Amino-7-phosphonoheptanoic acid solid |
A-167 |
|
| DL-2-Amino-7-phosphonoheptanoic acid approx. 95 % |
A5157 |
|
| DL-2-Amino-5-phosphonopentanoic acid solid |
A5282 |
|
| D(-)-2-Amino-5-phosphonopentanoic acid solid |
A-169 |
|
| CGS-19755 solid |
C-105 |
|
| CNS-1102 >98 % (HPLC) |
C4238 |
|
| D-CPP solid |
C-189 |
|
| (±)-CPP solid |
C-104 |
|
| d-3-Methoxy-N-methylmorphinan hydrobromide |
D2531 |
|
| Dextrorphan tartrate solid |
D-127 |
|
| Memantine hydrochloride min. 98 % (GC) |
M9292 |
|
| Pentamidine isethionate salt |
P0547 |
|
| Ro 25-6981 hydrochloride |
R7150 |
|
| Ro 8-4304 solid |
R8900 |
|
| Antagonists, Metabotropic |
|
|
| NPS 2390 min. 99 % (HPLC) solid |
N4786 |
mGluR1, mGluR5 |
| AIDA solid |
A-254 |
mGluR1 |
| CPCCOEt >98 % (HPLC) solid |
C9611 |
mGluR1 |
| (S)-2-Amino-2-methyl-4-phosphonobutyric acid hydrochloride synthetic solid |
M5560 |
mGluR4, mGluR6, mGluR7 |
| (±)-a-Methyl-(4-sulfonophenyl)glycine |
M5046 |
mGluR4, mGluR7, mGluR8 |
| 6-Methyl-2-(phenylethynyl)pyridine solid |
M5435 |
mGluR5 |
| SIB 1757 min. 99 % (HPLC) crystalline |
S9186 |
mGluR5 |
| SIB 1893 >99 % solid |
S9311 |
mGluR5 |
| L-(+)-2-Amino-3-phosphonopropionic acid min. 98 % |
A3690 |
Nonselective |
| DL-2-Amino-3-phosphonopropionic acid |
A4910 |
Nonselective |
| (+)-a-Methyl-4-carboxyphenylglycine solid |
M-196 |
Nonselective |
| (±)-a-Methyl-(4-carboxyphenyl)glycine |
M4796 |
Nonselective |
| Enzyme inhibitors |
|
|
| L-2-Aminoadipic acid |
A7275 |
Glutamine synthetase |
| DL-2-Aminoadipic acid min. 99 % |
A0637 |
Glutamine synthetase |
| D-2-Aminoadipic acid |
A7400 |
Less active enantiomer |
| Enzymes |
|
|
| L-Glutamate Oxidase from Streptomyces sp. Lyophilized powder min. 5 units/mg solid |
G0400 |
|
| L-Glutamine Synthetase from sheep brain Lyophilized powder min. 90 units/mg protein |
G6632 |
|
| Metabolites |
|
|
| L-Glutamine min. 99 % (TLC) |
G3126 |
|
| Others |
|
|
| NS 521 oxalate solid |
N7904 |
Neuroprotectant |
| Release inhibitors |
|
|
| Riluzole solid |
R-116 |
|
| Storage inhibitors |
|
|
| Chicago Sky Blue 6B powder |
C8679 |
|
| Transport inhibitors |
|
|
| L-2-Aminoadipic acid |
A7275 |
|
| DL-threo-b-Hydroxyaspartic acid |
H2775 |
|
| L-trans-Pyrrolidine-2,4-dicarboxylic acid min. 98 % |
P7575 |
|
| GABAergics |
|
back to top |
| Product Name |
Product # |
Specificity |
| Agonists |
|
|
| g-Aminobutyric acid min. 99 % |
A2129 |
Endogenous |
| 3-Amino-1-propanesulfonic acid sodium salt approx. 98 % |
A4147 |
GABAA |
| Chlormethiazole >98 % (HPLC) crystal |
C1240 |
GABAA |
| Etomidate >98 % (HPLC) powder |
E6530 |
GABAA |
| Felbamate |
F0778 |
GABAA |
| Piperidine-4-sulfonic acid |
P9159 |
GABAA |
| THIP hydrochloride solid |
T-101 |
GABAA |
| SB 205384 solid |
S7936 |
GABAA a3 b2 γ2 |
| Isoguvacine hydrochloride solid |
G-002 |
GABAA GABAC |
| Muscimol powder |
M1523 |
GABAA GABAC |
| Muscimol hydrobromide powder |
G-019 |
GABAA GABAC |
| 3-Aminopropylphosphonic acid |
A7162 |
GABAB |
| R(+)-Baclofen hydrochloride solid |
G-013 |
GABAB |
| SKF 97541 hydrochloride solid |
A-196 |
GABAB |
| S(-)-Baclofen hydrochloride solid |
G-014 |
GABAB, less active enantiomer |
| (E)-4-Amino-2-butenoic acid solid |
T1694 |
GABAC |
| Acenaphthenequinone tech. |
A-201 |
GABAC |
| Antagonists |
|
|
| (+)-Bicuculline crystalline |
B9130 |
GABAA |
| (-)-Bicuculline methiodide solid |
B6889 |
GABAA |
| 1(S),9(R)-(-)-Bicuculline methobromide solid |
B-103 |
GABAA |
| 1(S),9(R)-(-)-Bicuculline methochloride |
B-110 |
GABAA |
| tert-Butyl bicyclo[2.2.2]phosphorothionate solid |
B-104 |
GABAA |
| (1S,9R)-(+)-b-Hydrastine |
H8645 |
GABAA |
| SR-95531 solid |
S-106 |
GABAA |
| 2-Hydroxysaclofen min. 98 % (TLC) solid |
A6566 |
GABAB |
| Phaclofen solid |
P-118 |
GABAB |
| Saclofen solid |
S-166 |
GABAB |
| 4-Imidazoleacetic acid hydrochloride |
I0375 |
GABAC |
| Imidazole-4-acetic acid sodium salt |
I7013 |
GABAC |
| Picrotoxin powder |
P1675 |
GABAC |
| Picrotoxinin |
P8390 |
GABAC |
| SKF 97541 hydrochloride solid |
A-196 |
GABAC |
| (1,2,5,6-Tetrahydropyridin-4-yl)methylphosphinic acid solid |
T-200 |
GABAC |
| Cloflubicyne min. 95 % (NMR) solid |
C1983 |
Nonselective |
| Etbicyphat min. 95 % (NMR) solid |
E5277 |
Nonselective |
| Etbicythionat min. 98 % (NMR) solid |
E5402 |
Nonselective |
| Flucybene min. 95 % (NMR) solid |
F6551 |
Nonselective |
| Propybicyphat 95 % (NMR) solid |
P5489 |
Nonselective |
| Enzyme inhibitors |
|
|
| 3-Amino-2,3-dihydrobenzoic acid hydrochloride min. 98 % |
A3539 |
GABA transaminase |
| 4-Amino-5-hexynoic acid solid |
A-230 |
GABA transaminase |
| Vigabatrin |
V8261 |
GABA transaminase |
| S(+)-g-Vigabatrin solid |
V-113 |
GABA transaminase |
| L-Allylglycine min. 99 % (TLC) powder |
A7762 |
Glutamic acid decarboxylase |
| Enzymes |
|
|
| GABase from Pseudomonas fluorescens Lyophilized powder 0.5-2.0 units/mg protein |
G7509 |
|
| Modulators |
|
|
| CGP-13501 >98 % (HPLC) |
C0987 |
GABAB |
| Transport inhibitors |
|
|
| SKF 89976A hydrochloride >98 % (HPLC) |
S9066 |
GAT-1 |
| GABAA modulators |
|
|
| Alprazolam |
A8800 |
BDZ site |
| Carbamazepine powder |
C4024 |
BDZ site |
| Carbamazepine–HBC complex Free flowing powder |
C-162 |
BDZ site |
| Chlordiazepoxide hydrochloride |
C2517 |
BDZ site |
| 4'-Chlorodiazepam |
C5174 |
BDZ site |
| Clobazam |
C8414 |
BDZ site |
| Clonazepam powder |
C1277 |
BDZ site |
| Diazepam |
D0899 |
BDZ site |
| Estazolam |
E3638 |
BDZ site |
| Flunitrazepam |
F9261 |
BDZ site |
| Flurazepam dihydrochloride solid |
F-103 |
BDZ site |
| Gln-Ala-Thr-Val-Gly-Asp-Ile-Asn-Thr-Glu-Arg-Pro-Gly-Met-Leu-Asp-Phe-Thr-Gly-Lys min. 95 % (HPLC) |
G9898 |
BDZ site, peripheral |
| L-655,708 |
L9787 |
BDZ site a5 subunit |
| (±)-Lorazepam |
L1764 |
BDZ site |
| 3-Methyl-6-[3-(trifluoromethyl)phenyl]-1,2,4-triazolo[4,3-b]pyridazine |
M2922 |
BDZ site |
| Midazolam maleate salt |
M2419 |
BDZ site |
| Nitrazepam |
N3889 |
BDZ site |
| Oxazepam |
O5254 |
BDZ site |
| Triazolam |
T9772 |
BDZ site |
| Zolpidem >96 % solid |
Z-103 |
BDZ site |
| Zopiclone |
Z4900 |
BDZ site |
| b-Carboline-3-carboxylic acid N-methylamide |
E-006 |
BDZ site |
| Flumazenil >99 % (HPLC) solid |
F6300 |
BDZ site, central |
| N-Methyl-b-carboline-3-carboxamide:HBC complex Free flowing powder |
M-156 |
BDZ site |
| Methyl b-carboline-3-carboxylate solid |
E-002 |
BDZ site |
| Methyl 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate solid |
E-007 |
BDZ site |
| PK 11195 |
C0424 |
BDZ site, peripheral |
| Ro 15-4513 solid |
R-109 |
BDZ site |
| 3a,21-Dihydroxy-5a-pregnan-20-one min. 95 % |
P2016 |
Steroid site |
| 5a-Pregnan-3a-ol-11,20-dione |
P5052 |
Steroid site |
| 5a-Pregnan-3a-ol-20-one solid |
P8887 |
Steroid site |
| Dehydroisoandrosterone 3-sulfate sodium salt min. 98 % |
D5297 |
Steroid site |
| Pregnenolone sulfate sodium salt |
P-162 |
Steroid site |
| Oleamide min. 99 % |
O2136 |
|
| Metabolites |
|
|
| 4-Hydroxybutyric acid sodium salt |
H3635 |
|
| Others |
|
|
| NCS-356 solid |
N4034 |
Nonselective |
| NCS-382 solid |
N4159 |
Nonselective |
| Receptors |
|
|
| Benzodiazepine Receptor Lyophilized powder |
E-005 |
|
| Transport inhibitors |
|
|
| Guvacine hydrochloride >96 % solid |
G-007 |
|
| (±)-Nipecotic acid |
21,167-2 |
|
| NO-711 hydrochloride solid |
N-142 |
|
| Glycinergics |
|
back to top |
| Product Name |
Product # |
Specificity |
| Agonists |
|
|
| b-Alanine |
A7752 |
|
| Glycine min. 99 % (TLC) |
G7126 |
|
| Glycine hydrochloride min. 99 % (TLC) |
G2879 |
|
| Glycine sodium salt min. 99 % (TLC) |
G6761 |
|
| Hypotaurine min. 98 % (TLC) powder |
H1384 |
|
| D-Serine min. 98 % (TLC) |
S4250 |
|
| Taurine min. 99 % |
T0625 |
|
| Antagonists |
|
|
| Phenylbenzene w-phosphono-a-amino acid solid |
P-204 |
|
| Strychnine |
S0532 |
|
| Strychnine hydrochloride |
S8753 |
|
| Transport inhibitors |
|
|
| ALX 5407 hydrochloride solid >98 % (HPLC) |
A8977 |
GlyT-1 |
| ALX-1393 >98 % (HPLC) powder |
A5475 |
GlyT-2 |
| Other |
|
|
| Tetanus toxin from Clostridium tetani |
T3194 |
Glycine release blocker |
| Tetanus toxin C fragment from Clostridium tetani |
T3694 |
Glycine release blocker |
| Tetanus toxin C-fragment, FITC-labeled Clostridium tetani |
T3819 |
Glycine release blocker |
| Tetanus toxin C fragment, HRP labeled from Clostridium tetani Lyophilized powder |
T3944 |
Glycine release blocker |